Abstract
Recent advances in our understanding of voltage-gated sodium channels (NaVs) lead to the rational hypothesis that drugs capable of selective blockade of NaV subtypes may be a safe and effective strategy for the treatment of unwanted cough. Among the nine NaV subtypes (NaV1.1-NaV1.9), the afferent nerves involved in initiating cough, in common with nociceptive neurons in the somatosensory system, express mainly NaV1.7, NaV1.8, and NaV1.9. Although knowledge about the effect of selectively blocking these channels on the cough reflex is limited, their biophysical properties indicate that each may contribute to the hypertussive and allotussive state that typifies subacute and chronic nonproductive cough.
MeSH terms
-
Animals
-
Antitussive Agents / adverse effects
-
Antitussive Agents / therapeutic use*
-
Cough / drug therapy*
-
Cough / metabolism
-
Cough / physiopathology
-
Drug Design
-
Humans
-
Molecular Targeted Therapy
-
NAV1.7 Voltage-Gated Sodium Channel / drug effects*
-
NAV1.7 Voltage-Gated Sodium Channel / metabolism
-
NAV1.8 Voltage-Gated Sodium Channel / drug effects*
-
NAV1.8 Voltage-Gated Sodium Channel / metabolism
-
NAV1.9 Voltage-Gated Sodium Channel / drug effects
-
NAV1.9 Voltage-Gated Sodium Channel / metabolism
-
Neurons, Afferent / drug effects*
-
Neurons, Afferent / metabolism
-
Reflex / drug effects*
-
Sodium Channel Blockers / adverse effects
-
Sodium Channel Blockers / therapeutic use*
Substances
-
Antitussive Agents
-
NAV1.7 Voltage-Gated Sodium Channel
-
NAV1.8 Voltage-Gated Sodium Channel
-
NAV1.9 Voltage-Gated Sodium Channel
-
SCN10A protein, human
-
SCN11A protein, human
-
SCN9A protein, human
-
Sodium Channel Blockers